120 related articles for article (PubMed ID: 17675888)
1. Sevelamer and other anion-exchange resins in the prevention and treatment of hyperphosphataemia in chronic renal failure.
Wrong O; Harland C
Nephron Physiol; 2007; 107(1):p17-33. PubMed ID: 17675888
[TBL] [Abstract][Full Text] [Related]
2. Phosphate binders: Sevelamer in the prevention and treatment of hyperphosphataemia in chronic renal failure.
Spaia S
Hippokratia; 2011 Jan; 15(Suppl 1):22-6. PubMed ID: 21897754
[TBL] [Abstract][Full Text] [Related]
3. Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.
Pai AB; Shepler BM
Pharmacotherapy; 2009 May; 29(5):554-61. PubMed ID: 19397463
[TBL] [Abstract][Full Text] [Related]
4. Colestimide can be used as a phosphate binder to treat uraemia in end-stage renal disease patients.
Date T; Shigematsu T; Kawashita Y; Satake N; Morita K
Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii90-3. PubMed ID: 12771311
[TBL] [Abstract][Full Text] [Related]
5. Long-term comparison of sevelamer hydrochloride to calcium-containing phosphate binders.
Brewster UC; Ciampi MA; Abu-Alfa AK; Reilly RF
Nephrology (Carlton); 2006 Apr; 11(2):142-6. PubMed ID: 16669977
[TBL] [Abstract][Full Text] [Related]
6. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
Sprague SM
Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
[TBL] [Abstract][Full Text] [Related]
7. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial.
Garg JP; Chasan-Taber S; Blair A; Plone M; Bommer J; Raggi P; Chertow GM
Arthritis Rheum; 2005 Jan; 52(1):290-5. PubMed ID: 15641045
[TBL] [Abstract][Full Text] [Related]
8. Sevelamer reduces the efficacy of many other drugs.
Prescrire Int; 2009 Aug; 18(102):164-5. PubMed ID: 19743578
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of sevelamer in the treatment of uncontrolled hyperphosphataemia of haemodialysis patients.
Almirall J; Lopez T; Vallve M; Ruiz A; Llibre J; Betriu A
Nephron Clin Pract; 2004; 97(1):c17-22. PubMed ID: 15153763
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM
Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
[TBL] [Abstract][Full Text] [Related]
11. Does the choice of phosphate binder affect trace element levels in chronic kidney disease patients treated by regular haemodialysis?
Veighey K; Booth J; Davenport A
Nephrol Dial Transplant; 2011 Mar; 26(3):1006-10. PubMed ID: 20736253
[TBL] [Abstract][Full Text] [Related]
12. Effects of anion exchange resin as phosphate binder on serum phosphate and iPTH levels in normal rats.
Inoue H; Kagoshima M; Kaibara K
Int J Artif Organs; 2000 Apr; 23(4):243-9. PubMed ID: 10832658
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of sevelamer in patients with end-stage renal disease.
Manns B; Klarenbach S; Lee H; Culleton B; Shrive F; Tonelli M
Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182
[TBL] [Abstract][Full Text] [Related]
14. Improving phosphate-binder therapy as a way forward.
Hutchison AJ
Nephrol Dial Transplant; 2004 Mar; 19 Suppl 1():i19-24. PubMed ID: 15126650
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.
Evenepoel P; Selgas R; Caputo F; Foggensteiner L; Heaf JG; Ortiz A; Kelly A; Chasan-Taber S; Duggal A; Fan S
Nephrol Dial Transplant; 2009 Jan; 24(1):278-85. PubMed ID: 18820280
[TBL] [Abstract][Full Text] [Related]
16. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia.
Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kawasaki S;
Ther Apher Dial; 2014 Apr; 18(2):122-31. PubMed ID: 24720402
[TBL] [Abstract][Full Text] [Related]
17. Control of hyperphosphatemia beyond phosphate.
Evenepoel P
Kidney Int; 2007 Mar; 71(5):376-9. PubMed ID: 17315005
[TBL] [Abstract][Full Text] [Related]
18. Clinical effects of the new phosphorus binder, bixalomer in hemodialysis patients switched from sevelamer hydrochloride.
Gen S; Sasaki T; Saito K; Nobe K; Nodaira Y; Ikeda N
Ther Apher Dial; 2014 Jun; 18 Suppl 2():8-12. PubMed ID: 24975889
[TBL] [Abstract][Full Text] [Related]
19. Sevelamer.
Henderson J; Altmann P
Nephron Clin Pract; 2003; 94(3):c53-8. PubMed ID: 12902631
[TBL] [Abstract][Full Text] [Related]
20. Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis.
Takei T; Otsubo S; Uchida K; Matsugami K; Mimuro T; Kabaya T; Akiba T; Nitta K
Nephron Clin Pract; 2008; 108(4):c278-83. PubMed ID: 18434749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
